10.4244/EIJV7I1A11
•
May 17, 2011
Reappraisal of percutaneous aortic balloon valvuloplasty as a preliminary treatment strategy in the transcatheter aortic valve implantation era
Tissot C-M, Attias D, Himbert D, Ducrocq G, Iung B, Dilly M-P, Juliard J, Lepage L, Détaint D, Messika-Zeitoun D, Nataf P, Vahanian A
free
10.4244/EIJV7I1A13
•
May 17, 2011
Effect of paclitaxel elution from reservoirs with bioabsorbable polymer compared to a bare metal stent for the elective percutaneous treatment of de novo coronary stenosis: the EUROSTAR-II randomised clinical trial
Silber S, Gutiérrez-Chico J-L, Behrens S, Witzenbichler B, Wiemer M, Hoffmann S, Slagboom T, Harald D, Suryapranata H, Naber CK, Nienaber C, Chevalier B, Serruys PW
free
10.4244/EIJV7I1A14
•
May 17, 2011
Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials
Kereiakes D, Smits PC, Kedhi E, Parise H, Fahy M, Serruys PW, Stone GW
free
10.4244/EIJV7I1A15
•
May 17, 2011
PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses
Meredith I, Whitbourn R, Scott D, El-Jack S, Zambahari R, Stone GW, Teirstein P, Starzyk R, Allocco DJ, Dawkins K
free
10.4244/EIJV7I1A22
•
May 17, 2011
Impact of drug-eluting stent type on periprocedural myocardial necrosis
Wakabayashi K, Delhaye C, Mahmoudi M, Belle L, Ben-Dor I, Gaglia M, Suddath W, Satler L, Kent K, Pichard A, Lindsay J, Waksman R
free
